6. Cancer Risk Elevated With Glibenclamide Over Other Sulfonylureas

New research suggests Glyburide (also known as glibenclamide) to be associated with an increased risk for cancer compared with other diabetes drugs of the sulfonylurea class. The findings from a population-based cohort study was published in Diabetes Care. Glyburide seems to trigger the production of reactive oxygen species, a well-known pro-oncogenic factor, and this activity appears specific to glyburide and not to other sulfonylureas.

The U.K. Clinical Practice Research Datalink was used to conduct a cohort study among 52,600 patients newly prescribed glyburide or other second-generation sulfonylureas between 1 January 1988 and 31 July 2013. The overall use of glyburide among 3413 patients was associated with a nonsignificant 9% increased risk of any cancer when compared with the use of other second-generation sulfonylureas. Secondary analyses revealed significant duration- and dose-response increased risks. In addition to cancer, this drug has also been associated with important cardiovascular events.

Read More 


Share/Bookmark
This newsletter is published for free distribution through the Internet for doctors, patients and public for promoting healthy lifestyles.
For enquiries info@jothydev.net.
Please visit: jothydev.net | research.jothydev.com | diabscreenkerala.net | jothydev.com/newsletter